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Background
Tocilizumab (TCZ), an IL-6 receptor inhibitor, improves
arthritis and systemic symptoms associated with sys-
temic JIA. It may be a valuable option in patients with
JIA who show inadequate response to anti-TNF agents.
Aim
To analyze the short-term effectiveness and safety of
TCZ in patients with JIA refractory to anti-TNF agents.
Methods
All patients who received TCZ due to refractory disease
were included. All patients had exhibited anti-TNF pri-
mary or secondary failure. Data were retrieved from the
Rheumatology Section data base. TCZ was administered
intravenously at a dose of 8 mg/kg for patients > 30 Kg,
12 mg/Kg for patients < 30 Kg every 2 weeks. Efficacy
endpoints included improvement (ACR Pedi30), disap-
pearance of systemic symptoms, and reduction in corti-
costeroid dose.
Results
9 patients with JIA (7 systemic, 2 poliarticular, 7 F, 2 M)
were included. Median age at study entry was 10 years,
disease duration 6 years. They received TCZ for 3 to 9
months. Patients had been refractory to etanercept (9),
adalimumab (7) or infliximab (2). At baseline (medians):
active joints: 11, joints with limited motion: 4, wellbeing
(0-3): 0.1, disease activity (0-3): 0.45, ESR: 35 mm/h;
CHAQ > 0.5 3 patients, fever/rash 1 patient. Six patients
were receiving corticosteroids. All patients met improve-
ment criteria, 7 before the 3rd TCZ infusion. At 1
month after TCZ therapy began: active joints: 4, joints
with limited motion: 3, wellbeing: 0.05, disease activity:
0.24, ESR: 3 mm/h; CHAQ > 0.5 1 patient, fever/rash 0
patient. During the treatment, 4 patients reduced dose
(< 50%) of corticosteroids. No side effects were
recorded.
Conclusions
Tocilizumab seems to be effective and safe with a rapid
onset of action in children with anti-TNF refractory JIA.
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